Comparison of Drainage Methods in Minimally Invasive Esophagectomy (DEMURE)
Launched by RUIJIN HOSPITAL · May 26, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at different ways to manage drainage after a specific type of surgery for esophageal cancer called minimally invasive esophagectomy. The researchers want to compare three methods of drainage to see which one leads to less pain and fewer complications after surgery. By understanding which method works best, they hope to improve recovery for patients undergoing this procedure.
To participate in the trial, you need to be at least 18 years old and have a confirmed diagnosis of esophageal cancer that requires surgery involving three incisions: one in the neck, one in the chest, and one in the abdomen. You should be in good overall health (classes I-III on the ASA scale) and not have a history of chronic pain or serious heart and lung issues. If you join, you can expect close monitoring during your surgery and recovery, and you’ll help provide important information that could benefit future patients. The trial is currently looking for participants, so if this sounds like you or someone you know, it could be a great opportunity to contribute to medical research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Pathologically confirmed esophageal cancer requiring three-incision esophagectomy (cervical, thoracic, and abdominal incisions)
- • ASA physical status class I-III
- Exclusion Criteria:
- • History of chronic pain or long-term use of analgesics prior to surgery
- • Severe cardiopulmonary dysfunction (e.g., FEV1 \<50%)
- • Coagulation disorders or patients undergoing reoperation
- • Intraoperative findings of extensive pleural adhesions, combined resection of adjacent organs, or other conditions deemed by the investigator to warrant exclusion
About Ruijin Hospital
Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, is a leading medical institution in China recognized for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, Ruijin Hospital integrates cutting-edge medical practices with rigorous scientific investigation. The hospital's multidisciplinary teams are dedicated to developing new therapeutic approaches, improving patient outcomes, and contributing to global medical knowledge. As a sponsor of clinical trials, Ruijin Hospital ensures adherence to the highest ethical standards and regulatory compliance, fostering an environment of collaboration and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Hecheng Li, PhD, MD
Principal Investigator
Ruijin Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported